BELLUS Health is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders. The Company's product candidate, BLU-5937, is being developed for the treatment of chronic cough and chronic pruritus. Show more
Location: 275 Armand-Frappier Blvd, Quebec, H7V 4A7, Canada | Website: www.bellushealth.com | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing
Market Cap
0.00
52 Wk Range
$N/A - $N/A
Previous Close
$14.74
Open
$14.74
Volume
3,449,256
Day Range
$14.74 - $14.75
Enterprise Value
0.00
Cash
0.00
Avg Qtr Burn
N/A
Insider Ownership
10.26%
Institutional Own.
90.41%
Qtr Updated
06/30/24
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
| Drug & Indication | Stage & Event | Catalyst Date |
|---|---|---|
BLU-5937 (P2X3 antagonist) Details Chronic pruritus, Atopic pruritus | Failed Discontinued |